Safety and Efficacy of Ripasudil in Japanese Patients with Glaucoma or Ocular Hypertension: 3-month Interim Analysis of ROCK-J, a Post-Marketing Surveillance Study

Abstract

Introduction

To evaluate the safety and intraocular pressure (IOP)-lowering effects of a ripasudil 0.4% ophthalmic solution in Japanese patients with glaucoma and ocular hypertension (OH) as a post-marketing surveillance.

Methods

This was a 2-year prospective observational study in patients with glaucoma or OH who had not previously received ripasudil. Patients registered in the study using a central internet-based system from June 1, 2015 to April 30, 2017. Data on adverse drug reactions (ADRs) and IOP were collected and analysed from the first 3 months of ripasudil treatment.

Results

Of the 3058 patients in the safety analysis set, 3016 had IOP data and were included in the efficacy analysis. ADRs were seen in 244 (8.0%) of the 3058 patients. IOP decreased significantly in patients with primary open-angle glaucoma (− 2.9 ± 4.2 mmHg; p < 0.001), normal tension glaucoma (− 1.7 ± 2.4 mmHg; p < 0.001), primary angle-closure glaucoma (− 3.9 ± 5.3 mmHg; p < 0.001), and OH (− 3.8 ± 5.8 mmHg; p < 0.001). Significant IOP reduction was also noted in exfoliation glaucoma (− 3.0 ± 5.5 mmHg; p < 0.001), uveitis-associated glaucoma (− 4.7 ± 7.2 mmHg; p < 0.001) and steroid glaucoma (− 5.5 ± 6.0 mmHg; p < 0.001), but not for neovascular glaucoma (− 2.8 ± 12.1 mmHg; p = 0.669).

Conclusion

Ripasudil was safe and effective in the treatment of glaucoma and OH in Japanese patients, with a low incidence of ADRs or treatment discontinuation, and reduced IOP after 3 months of treatment.

Funding

Kowa Company, Ltd., Tokyo, Japan.

http://bit.ly/2GVpUUq